Tysabri news from FierceBiotech
News
Icahn aims for Biogen control
Carl Icahn says that Biogen Idec essentially ran a sham when it put itself up for auction Read more...
FDA more friendly to approvable than approved
You've probably already heard that FDA approvals took a nasty dive last year, with analysts Read more...
Biogen shares deflate as it gives up on sale
After ratcheting up expectations of a takeover and a hefty premium for stockholders, Biogen Idec pulled the rug out from Read more...
Biogen stock sinks as investors do reality check
Maybe all those high-flying expectations about a big-dollar buyout for Biogen Idec were a tad inflated. The Boston Globe is Read more...
Sources: Biogen gets bidders, with Pfizer in lead
The Financial Times is reporting some tantalizing details about the bidding for Biogen Idec, the biotech based in Cambridge, MA, that Read more...
Biogen Idec in play after Icahn makes his move
Biotech powerhouse Biogen Idec has brought in some of Wall Streets top dealmakers to explore a possible sale of the company, which would fetch well over $20 billion. In fact, says Biogen Idec, the Read more...
SPOTLIGHT: No new PML cases for Tysabri
As of September, there have been no new cases of the potentially fatal brain disease PML among patients taking Tysabri. The drug was pulled from the market last year after several patients taking the Read more...
Watchdog endorses use of Tysabri for severe MS
Biogen Idec and Elan won an important endorsement for Tysabri with a recommendation from Britain's cost-effectiveness watchdog--the National Institute for Health and Clinical Excellence--that the Read more...
FDA committee backs Tysabri for Crohn's
Elan and Biogen Idec have won the backing of an FDA expert committee in its quest to gain regulatory approval for Tysabri as a therapy for Crohn's disease. The backing came for the use of Tysabri for Read more...
After reintroduction, Tysabri builds patient base
A year after Tysabri was reintroduced for multiple sclerosis, its manufacturers say that 14,000 patients Read more...
Get more Tysabri coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends